Standard Life Aberdeen plc raised its stake in shares of Humana Inc (NYSE:HUM) by 20.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 88,931 shares of the insurance provider’s stock after acquiring an additional 14,875 shares during the period. Standard Life Aberdeen plc’s holdings in Humana were worth $32,595,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Lighthouse Financial Advisors Inc. purchased a new stake in Humana during the 4th quarter valued at approximately $31,000. Evoke Wealth LLC purchased a new stake in Humana during the 3rd quarter valued at approximately $26,000. Penserra Capital Management LLC purchased a new stake in Humana during the 3rd quarter valued at approximately $31,000. Psagot Investment House Ltd. purchased a new stake in Humana during the 3rd quarter valued at approximately $35,000. Finally, Tompkins Financial Corp purchased a new stake in Humana during the 4th quarter valued at approximately $55,000. 94.02% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have recently issued reports on the company. Mizuho reissued a “buy” rating and set a $405.00 target price on shares of Humana in a research note on Friday, February 14th. Morgan Stanley raised their price objective on Humana from $457.00 to $460.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Cantor Fitzgerald raised their target price on Humana from $345.00 to $400.00 and gave the company an “overweight” rating in a research note on Wednesday, February 5th. Barclays lifted their price target on Humana from $327.00 to $358.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Finally, Credit Suisse Group lifted their price target on Humana from $378.00 to $400.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $384.00.
NYSE:HUM traded up $35.47 during midday trading on Thursday, hitting $304.48. 2,204,111 shares of the stock were exchanged, compared to its average volume of 1,559,200. The company has a market capitalization of $30.92 billion, a price-to-earnings ratio of 15.16, a P/E/G ratio of 0.90 and a beta of 0.89. Humana Inc has a one year low of $208.25 and a one year high of $384.99. The business has a 50-day moving average price of $331.10 and a two-hundred day moving average price of $322.94. The company has a current ratio of 1.82, a quick ratio of 1.82 and a debt-to-equity ratio of 0.41.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 5th. The insurance provider reported $2.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.20 by $0.08. The company had revenue of $16.30 billion for the quarter, compared to analysts’ expectations of $16.15 billion. Humana had a return on equity of 20.89% and a net margin of 4.17%. The firm’s revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.65 earnings per share. Sell-side analysts forecast that Humana Inc will post 18.64 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Tuesday, March 31st will be issued a $0.625 dividend. The ex-dividend date is Monday, March 30th. This represents a $2.50 annualized dividend and a dividend yield of 0.82%. This is a boost from Humana’s previous quarterly dividend of $0.55. Humana’s dividend payout ratio is currently 12.31%.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Inverted Yield Curve
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.